AB Science SA

AB Science announces the successful completion of a EUR 1.8 million private placement

20 مايو 2025 00:49:42 بحسب Nasdaq GlobeNewswire

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

19 مايو 2025 00:51:54 بحسب Nasdaq GlobeNewswire

AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib

15 مايو 2025 01:07:23 بحسب Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2024 and provides an update on its activities

12 مايو 2025 01:14:35 بحسب Nasdaq GlobeNewswire

AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting

05 مايو 2025 11:03:42 بحسب Nasdaq GlobeNewswire

AB Science will publish its 2024 annual financial report on May 9, 2025

01 مايو 2025 03:06:22 بحسب Nasdaq GlobeNewswire

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23 أبريل 2025 11:59:03 بحسب Nasdaq GlobeNewswire

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

14 أبريل 2025 11:02:30 بحسب Nasdaq GlobeNewswire

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

04 مارس 2025 01:35:15 بحسب Nasdaq GlobeNewswire

AB Science today provides an update on its masitinib platform

29 يناير 2025 12:03:14 بحسب Nasdaq GlobeNewswire

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

24 يناير 2025 11:01:01 بحسب Nasdaq GlobeNewswire

AB Science will participate in the Biomed Forum investors conference

22 يناير 2025 11:59:47 بحسب Nasdaq GlobeNewswire

AB Science provides a summary of the webcast held on December 16, 2024

17 ديسمبر 2024 12:04:08 بحسب Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

11 ديسمبر 2024 11:06:34 بحسب Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 أكتوبر 2024 11:47:33 بحسب Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 أكتوبر 2024 12:28:54 بحسب Nasdaq GlobeNewswire

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10 أكتوبر 2024 01:28:04 بحسب Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2024 half-year financial report

30 سبتمبر 2024 11:33:35 بحسب Nasdaq GlobeNewswire

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

26 سبتمبر 2024 01:28:30 بحسب Nasdaq GlobeNewswire

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 سبتمبر 2024 10:51:06 بحسب Nasdaq GlobeNewswire